Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability of KRN330 in
patients with relapsed or refractory advanced or metastatic colorectal cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Kirin Pharmaceutical Development, Inc. Kyowa Kirin, Inc.